Articles By Jack Cush, MD
Intrathecal Methotrexate for Cerebritis (3.31.2023)
Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow.com.
Read Article
Alcohol Differences in Urate Level Elevation
Does serum urate elevation differ with different types of alcohol consumption? A Japanese study shows beer and wine was associated with high and moderate increases in uric acid but less so with sake.
Read Article
Gout - Hot Topics in March 2023
A number of new reports this month shed new light on old issues in Gout.
Read Article
Atopic Disease Increases Osteoarthritis Risk
Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis.
Read Article
LAVLI - A New Autoinflammatory Disorder
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein).
Read Article
Night Splinting for Carpal Tunnel (3.24.2023)
Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
Read Article
Faith and Miracle Larry
This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020. During this time, his close friend, Larry, contracted COVID-19 and was hospitalized, intubated and put on mechanical ventilation for nearly 2 months.
Read Article
2022 EULAR Recommendations for ANCA-associated Vasculitis
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Read Article
Polypharmacy Increased in Psoriatic Arthritis
Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.
Read Article
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
Read Article
